secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001437749-25-014880
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar presents ALXN1840 late-breaker data at EASL showing sustained efficacy and safety over 2.6 years
--------------------------------------------------------------------------------

- Pooled analysis from three trials (n=255) shows sustained improvements in UWDRS Part II/III and copper mobilization.
- Fewer than 5% of patients had a drug-related serious adverse event; no renal/urinary SAEs reported.
- ALXN1840 improved CGI-I and New Wilson Index vs. standard of care; patients reported higher convenience.
- Median treatment duration 961 days (efficacy) and 943.5 days (safety) across four trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925014880/0001437749-25-014880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925014880/mnpr20250505_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-014880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer